近日,由中国药科大学与江苏威凯尔医药科技有限公司联合申报的化药1.1类抗血栓新药“维卡格雷片”(Vicagrel Tablets)一次性获得了国家食品药品监督管理总局颁发的I至III期药物临床试验批件(批件号:2015L00539等)。维卡格雷是由中国药科大学药物科学研究院“长江学者”特聘教授孙宏斌课题组开发研制、并与江苏威凯尔医药科技有限公司通过产学研合作共同开发的抗血小板聚集新药。临床前研究表明,维卡格雷与临床上广泛使用的抗血栓药 Recently, China Pharmaceutical University and Jiangsu Weikel Pharmaceutical Technology Co., Ltd. jointly declared that the 1.1 class of anti-thrombotic drugs “Viccarrel Tablets” one-time access to the State Food and Drug Administration issued Phase I to III drug clinical trial approval (batch number: 2015L00539, etc.). Vicargale was developed by the research team of Sun Hongbin, chair professor of Institute of Pharmaceutical Sciences of China Pharmaceutical University and chair of Changjiang Scholar, and developed a new anti-platelet aggregation drug with Jiangsu Weikel Pharmaceutical Technology Co., Ltd. through the cooperation of production, study and research. Preclinical studies have shown that vicarrage and clinically widely used anti-thrombotic drugs